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Abstract 
 
In Cameroon, the main determinant of cancer mortality is the advanced stage at the time of diagnosis. The purpose 
of this work is to determine the relationship between C-reactive Protein (CRP) concentration and advanced cancer 
stage. This is a cross-sectional study conducted at Yaoundé General Hospital. 276 naive patients with histological 
evidence of cancer were included in this study. Serum CRP level was correlated with the specific characteristics of 
the tumor. The study population was made of 74% women and 26% men with a minimum age of 22 years and a 
maximum age of 80 with an average age of 46 years. The cancer type with the highest prevalence was breast cancer 
(43.5%), followed by Kaposi's sarcoma (8.7%), Non Hodgkin Lymphoma (8.7%), CRP values were Classified into 
two  groups based on pathological values (CRP≥ 6 mg/l) and non-pathological values (CRP <6 mg/l). The elevated 
CRP concentration was not significantly associated with the presence of metastasis M (P = 0.074), T-cancer stage (P 
= 0.09), N-lymph nodes (P = 0.111), advanced histological grade G-3 (P = 0.115) and cancer type (P = 0.124). Our 
study shows that elevated serum CRP is not a marker of cancer extension. 
 
Keywords: CRP, cancer, inflammation, prognostic. 
Introduction 
Inflammation is the response of vascularized tissues to 
aggression (microorganism, trauma, ischemia). It has 
several roles: natural defense and repair of injured 
tissues [1]. It can have several causes: stress, 
environmental pollutants, viruses, bacteria and food 
[2].  
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Inflammation can occur biologically by the decrease of 
certain markers, namely albumin, ferritin and by the 
increase of other markers such as: serum amyloid A 
(SAA), CRP (protein-C reactive) [3]. However, 
inflammation in the cancerous process could be 
materialized by increase in certain serum proteins, 
including CRP. Therefore, it has been shown that a 
high level of CRP can be used as a predictive marker 
for metastases in penile cancers [3]. Similarly, studies 
have shown that a high level of CRP can be used as a 
prognostic marker of poor survival [4]. In addition, the 
first marker of poor survival in patients with cancer 
was advanced stage [5]. This advanced stage, which is 
95% at the time of diagnosis, is the main determinant 
of high mortality due to cancer [6]. Methods for 
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evaluating the spread of cancer, including medical 
imaging, are very expensive and still have limits 
because their resolotion is on average 10 millimeters, 
which is equivalent to a nodule of one billion cells 
which could go unnoticed at the time of diagnosis[7]. 
Then the study consisted of showing whether there 
might be a relationship between biological markers 
(CRPs) and the extension of cancer.  
Material and methods 
We carried out a cross-sectional study at the Yaoundé 
General Hospital, the Oncology Service and the 
Laboratory.The studylasted over a period of 10 months, 
from March to December 2014. None of our patients 
had initiated chemotherapy. The study was approved 
by the Institutional Committee of Ethics of Research 
for Human Health of the UCAC School of Health 
Sciences. We had 69 patients by a consecutive non-
probabilistic sampling recruited during consultations 
and meeting the criteria of inclusion of age 21 years 
and older;  patients with histologically proven cancer, 
people with an extension report including at least: chest 
x-ray and pelvic ultrasound, Clinical examination 
(tumor examination ie finding any superficial ganglion 
and lesion that may notice Kaposi's Sarcoma) and 
patients who had not yet received treatment. Due to the 
small sample size, werecruited 207 patients coming 
from a cohort study from 2015 to 2017. We took these 
patients because they had the same features with the 
first group of population and they had all the 
information needed.  patients who had cancer in 
addition to other diseases were recruited and this factor 
was taken into account in the statistical analysis. 
Metastasis nodules were determined by medical 
imaging techniques (scanner, MRI). The histological 
parameters of the extension were determined by the 
pathological examinations and classified according to 
the TNM 2002 classification. The information obtained 
from the patient from a standardized questionnaire 
were classified in socio-demographic characteristics 
such as sex, age. Then in clinical characters: size, 
weight, types of cancer, primary tumor diameter, 
presence of ganglion, number and localization, 
presence of inflammatory syndrome, presence of 
metastases, number and localization; in 
anatomopathological parameters, grade and stage; 
biological characteristics: CRP and NFS. The CRP 
value was split into two (<6 mg / l and ≥ 6mg / l) 
according to the suggestion of Saito et al., 2007 and 
according to our context where a CRP value ≥ 6mg / l 
is pathological. 
 
Statistics  
Continuous variables were reported as mean value and 
standard deviation (SD) or median value and 
interquartile ranges (IQR) in the case of parametric or 
non-parametric distribution, respectively. Chi2 and 
Fisher’s exact tests were conducted to assess 
correlations of nominal covariate distributions and 
CRP-groups. The t-test (in case of parametric) was 
applied to compare metric variables between two or 
more subgroups. SPSS 20.0 was used for statistical 
assessment. In all tests, a two-sided p<0.05 was 
considered to indicate significance. 
Results 
Our patient population with an available pre-treatment 
CRP value consisted of 72 (26.1%) men and 204 
(73.9%) women had a mean (median) age of 50.17 (46) 
years (22-80). The median body mass index (BMI) for 
all patients was 27.61 kg/m2 (IQR, 23.07 –30.12). 
Breast cancer was the most represented with 43.5%, 
followed by Kaposi sarcoma (8.7%), NHL (8.7%), 
cervix cancer (7.2%), prostate cancer and multiple 
myeloma have respectively 4.2% and others cancers 
(22%) includingmalignant melanoma, lymphangitis, 
malignant hemangioendothelium, adrenal cancer, 
ovarian cancer, vaginal cancer, placenta cancer, 
pancreatic cancer, liver cancer, cavum cancer, colon 
cancer, thyroid cancer, esophagus and bronchial cancer 
in figure 1. Detailed patients’ and tumour 
characteristics including stage and grade are 
summarized in Table 1 and Table2. 
The mean pre-treatment CRP value of all 276 
evaluable patients was 35.84 (12.0) mg/l. The mean 
CRP value in the two subgroups was 5.00(4.04) and 
31.00 (55.07) mg/l, respectively. Both groups were 
comparable concerning the distribution of sexes 
(p=0.016; Fisher’s exact test, Table 1), the BMI value 
(p=0.221; t-test) and tumour location (p=0.124, 
Fisher’s exact test; Table 2) as well as age, patients 
with a CRP <6mg/l tended to be older (p=0.47; t-test) 
Table 1.  
The CRP-level was not correlated significantly with the 
tumour stage: 24.64 and 42.03% of all patients with a 
CRP<6 and ≥ 6mg/l,suffered from invasive disease 
(pT≥3) at the time diagnosis (p<0.51, Fisher’s exact 
test). Accordingly, the median CRP value was not 
significantly lower in those patients with superficial 
compared to invasive cancer (9.0 vs. 12.0 mg/l; 
p<0.253, t-test). The risk of presenting nodal disease 
(p=0,111, Fisher’s exact test, Table 2) was not 
increased significantly as comparedto distant 
metastasis (p=0,074, Fisher’s exact test; Table 2) in 
patients with a CRP value ≥ 6mg/l. Moreover, elevated 
CRP-levels were found in 18.42, 10.52 and 26.31% of 
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patients with G1, G2 and G3 tumours, respectively (p<0,115, Chi2 test, Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1: Distribution of the study population according to the type of tumor 
Table 1 : Characteristics of the population 
Variables  CRP<6(%) CRP≥6(%) P-value Tests 
Age, mean(Years)±SD 51,54 ±(15,467) 49,35±(9,584) 0,470 t-test 
BMI, mean(Kg/m2) ±SD 27,36±(5,73) 23,93±(5,17) 0.221 t-test 
Sexe    0,097 Fisher 
F 88(31.88) 116(42.03)   
M 16(5.79) 56(20.29)   
Table  2: Clincal 
 
Variables  CRP<6(%) CRP≥6(%) P-value Tests 
Types de cancers   0.124 Fisher  
Breast Cancer 64(53,3) 56(46,7)   
Others  cancers 40(25,7) 116(74,3)   
Metastasis    0,074 Fisher 
M+ 4(25) 72(27, 7)   
M- 12(75) 188(72, 3)   
Lymph node     0,111 Fisher 
N+ 60(50) 60(50)   
N- 44( 30,6) 100(69, 4)   
Leucocytes   0,033 Chi-square 
˂4000 28(58,3) 20(41,7)   
4000-10000 56(42,4) 76(57,6)   
˃10000 4(8,3) 44(91,7)   
Stade    0.09 Fisher 
≤ T-2 32(45,5) 40(55,5)   
≥ T-3 68(37,8) 112(62,2)   
Grade    0,115 Chi-square 
G1 20(13.15) 28(26.32)   
International Journal of Health and Clinical Research, 2018;1(1):33-37                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Simeni et al                               International Journal of Health and Clinical Research, 2018; 1(1):33-37 
www.ijhcr.com                              
        36 
 
G-2 24(15.78) 16(10.52)   
G-3 24(37,5) 40(62,5)   
Discussion 
CRP is an essential biomarker of the inflammatory 
response. Several studies have indicated that serum 
CRP levels are an independent predictor of prognosis 
for various solid tumors, HL, and NHL [8, 9] . 
However, the prognostic role of serum CRP levels in 
many cancers taken on the same time remains unclear. 
The distinct characteristics of prominent regional 
necrosis and inflammation observed in cancer patients 
prompted us to analyze the impact of CRP on the 
prognostic outcome of patients with cancer. To the best 
of our knowledge, the present study represents the 
largest series and the first one to date examining the 
prognostic value of serum CRP levels in several types 
of cancer at the same time.  Our study aimed to show 
the association between CRP levels and the extension 
of cancers. Like the study titled "Preoperative serum C-
reactive protein: a prognostic marker in patients with 
urothelial carcinoma", she addressed the relationship 
between CRP and cancer extension. It took into 
account the extension in the three categories TNM 
(stage T, lymph node and metastasis) thus allowing a 
more holistic approach to the extension of the tumor. It 
appears that patients with a CRP level ≥ 6 mg/l (high) 
were predominantly at an advanced T stage of cancer 
(62.2% vs 55.5%). But this difference was not 
significant P = 0.09as in the case of Ya-Jun Li et al, 
2013 (P = 0.145). In oncology, tumor diameter is used 
to refer to the potentially palpable stage of cancer. 
However, there is no significant relationship between 
elevated CRP level and tumor diameter (P = 0.162). 
This result confirms that the level of CRP is not related 
to the stage T of the tumor. Similarly, Ya-Jun Li[10] 
corroborates this result by showing in his study that a 
diameter greater than or equal to 5 cm showed a non-
significant association with the CRP level (P = 0.289). 
Once again, a non significant association was found 
between elevated CRP and the presence of lymph node 
(P = 0.111) and metastasis (p = 0,074). These results 
are close to the data provided by Cao[9] who showed a 
non significant association between lymphadenopathy 
(P = 0.297), metastasis (P = 0.183) and elevated CRP. 
Thus, our study shows that high CRP levels in patients 
with cancer and more at advanced stages reveal that the 
cancer is characterized by an inflammatory process. In 
contrast to the results found, several authors have 
shown the role of CRP in prognosis, taking into 
account advanced stage and survival. It appears that 
high circulating CRP levels correlated significantly 
with lymph node metastasis and survival in patients 
with oral SCC [11]. Ishizuka et al. [12] evaluated 
several potential clinical factors and biological markers 
in a large series of patients with locally advanced 
colorectal cancer. Multivariate analysis identified high 
CRP levels as an indicator or predictor of both nodal 
and distant metastasis in T3 colorectal cancer. Neuss et 
al. [13] demonstrated that the preoperative serum CRP 
level correlated significantly with the number of lymph 
node metastases found during radical lymph node 
dissection in stage III melanoma patients. Thus the role 
of CRP in cancer is still to be demonstrated because as 
shown in the review of Katriina Heikkila[14] nine large 
prospective studies identified in this review, four 
studies reported no association between circulating 
CRP and breast, prostate and colorectal cancers, but 
five studies provided some evidence that CRP could be 
related to colorectal and lung cancers. More over, 
several studies cumulate biases such as limitations in 
the selection of participants. In all, 41 studies did not 
contain an adequate description of how the participants 
had been selected that could influence the results 
found. Most prevalent studies have reported higher C 
reactive protein (CRP) concentrations in patients with 
cancer than in healthy controls and participants with 
some benign conditions, but this can be due to reverse 
causality, survival bias or confounding.However, some 
limitations of our study are that CRP was measured at 
one point in time. Therefore intra-individual variations 
were not considered. Furthermore, general diseases 
associated with possible higher inflammation markers 
like diabetes mellitus or Morbus Crohn were not taken 
into consideration due to lack of information. 
Conclusion 
At the end of our study whose objective was to 
evaluate the association between the rate of CRP and 
parameters of extension of cancers in the patients 
followed at the general hospital of Yaoundé, we found 
that there was a significant association between the 
high CRP level and the type of cancer. in other hand, 
the high rate of CRP was not significantly associated 
with the TNM parameters T (P=0.09), N (P=0,111) and 
M (P=0,074). hence circulating serum CRP level could 
not be a pronostic marker of cancer. 
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